CIT-话题@MedSci

#CIT#

176篇内容 | 3547人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1738564, encodeId=b05f1e3856442, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=City of Hope正在招募患者进行HPV相关癌症的人体T细胞试验, objectType=article, longId=177802, objectId=58ec1e780208, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58ec1e780208, replyNumber=0, likeNumber=46, createdTime=2020-03-18, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58ec1e780208, moduleTitle=City of Hope正在招募患者进行HPV相关癌症的人体T细胞试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58ec1e780208)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738565, encodeId=36111e3856584, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=每周一次的somapacitan治疗生长激素缺乏症儿童，效果与每日一次的生长激素相当, objectType=article, longId=179928, objectId=4a451e992828, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a451e992828, replyNumber=0, likeNumber=62, createdTime=2019-10-23, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a451e992828, moduleTitle=每周一次的somapacitan治疗生长激素缺乏症儿童，效果与每日一次的生长激素相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a451e992828)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738551, encodeId=2ec11e38551b8, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=第十七届中国介入心脏病学大会（CIT2019)|寿锡凌：ACS合并高出血风险患者PCI术后双抗的复杂性, objectType=article, longId=163378, objectId=adba1633e8c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adba1633e8c7, replyNumber=0, likeNumber=67, createdTime=2019-04-15, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adba1633e8c7, moduleTitle=第十七届中国介入心脏病学大会（CIT2019)|寿锡凌：ACS合并高出血风险患者PCI术后双抗的复杂性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=adba1633e8c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738556, encodeId=ca501e38556ea, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Lancet：Upadacitinib单药是否可替代甲氨蝶呤治疗类风湿性关节炎？, objectType=article, longId=166786, objectId=cc2b166e864d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc2b166e864d, replyNumber=0, likeNumber=64, createdTime=2020-02-09, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc2b166e864d, moduleTitle=Lancet：Upadacitinib单药是否可替代甲氨蝶呤治疗类风湿性关节炎？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc2b166e864d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738553, encodeId=de4d1e385533d, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=第十七届中国介入心脏病学大会（CIT2019)|高鑫：经皮肺动脉血管成形术围术期管理, objectType=article, longId=163529, objectId=1b3e16352912, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b3e16352912, replyNumber=0, likeNumber=90, createdTime=2019-11-11, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b3e16352912, moduleTitle=第十七届中国介入心脏病学大会（CIT2019)|高鑫：经皮肺动脉血管成形术围术期管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b3e16352912)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738557, encodeId=96271e3855707, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Lancet：Upadacitinib单药治疗甲氨蝶呤应答不充分的类风湿性关节炎, objectType=article, longId=167017, objectId=ba5d16e017b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba5d16e017b4, replyNumber=0, likeNumber=73, createdTime=2019-07-29, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba5d16e017b4, moduleTitle=Lancet：Upadacitinib单药治疗甲氨蝶呤应答不充分的类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba5d16e017b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738559, encodeId=c74f1e3855976, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Resuscitation：3.9万猝死人群研究，三成猝死者在事发前三月内曾去过急诊科, objectType=article, longId=167560, objectId=1e8716e56080, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e8716e56080, replyNumber=0, likeNumber=72, createdTime=2020-03-02, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e8716e56080, moduleTitle=Resuscitation：3.9万猝死人群研究，三成猝死者在事发前三月内曾去过急诊科, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e8716e56080)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738552, encodeId=ccdd1e38552f7, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=第十七届中国介入心脏病学大会（CIT2019)|徐仲英：老年人房间隔缺损的介入治疗, objectType=article, longId=163382, objectId=5d931633827a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d931633827a, replyNumber=0, likeNumber=67, createdTime=2019-07-21, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d931633827a, moduleTitle=第十七届中国介入心脏病学大会（CIT2019)|徐仲英：老年人房间隔缺损的介入治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d931633827a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738560, encodeId=d2ba1e3856020, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=MedSci期刊数据库中更新全新citescore, objectType=article, longId=167898, objectId=338916e8983d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=338916e8983d, replyNumber=0, likeNumber=65, createdTime=2019-11-20, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=338916e8983d, moduleTitle=MedSci期刊数据库中更新全新citescore, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=338916e8983d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738558, encodeId=ab761e38558a1, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果, objectType=article, longId=167491, objectId=1e2a16e491c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e2a16e491c8, replyNumber=0, likeNumber=63, createdTime=2020-02-03, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e2a16e491c8, moduleTitle=The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e2a16e491c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738541, encodeId=d4521e38541c2, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=NEJM：sacituzumab govitecan-hziy治疗难治性转移性三阴性乳腺癌, objectType=article, longId=160705, objectId=9197160e05e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9197160e05e2, replyNumber=0, likeNumber=94, createdTime=2019-11-01, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9197160e05e2, moduleTitle=NEJM：sacituzumab govitecan-hziy治疗难治性转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9197160e05e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738539, encodeId=bfdf1e385393a, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=AbbVie向美国FDA提交Upadacitinib治疗中重度类风湿性关节炎的新药申请, objectType=article, longId=156675, objectId=905a1566e5bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=905a1566e5bb, replyNumber=0, likeNumber=69, createdTime=2019-09-09, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=905a1566e5bb, moduleTitle=AbbVie向美国FDA提交Upadacitinib治疗中重度类风湿性关节炎的新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=905a1566e5bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738549, encodeId=70991e38549f5, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=第十七届中国介入心脏病学大会（CIT2019)|陈韵岱：心肌微循环灌注的评价方法, objectType=article, longId=163369, objectId=532716336939, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=532716336939, replyNumber=0, likeNumber=66, createdTime=2020-03-12, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=532716336939, moduleTitle=第十七届中国介入心脏病学大会（CIT2019)|陈韵岱：心肌微循环灌注的评价方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=532716336939)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738550, encodeId=1f7c1e3855070, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=第十七届中国介入心脏病学大会（CIT2019)|傅向华：急性心肌梗死再灌注治疗与微循环保护进展, objectType=article, longId=163370, objectId=4e131633e0b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e131633e0b0, replyNumber=0, likeNumber=112, createdTime=2020-02-26, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e131633e0b0, moduleTitle=第十七届中国介入心脏病学大会（CIT2019)|傅向华：急性心肌梗死再灌注治疗与微循环保护进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e131633e0b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738544, encodeId=e2e61e38544e3, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=第十七届中国介入心脏病学大会（CIT2019）|蒋世良：中国先心病介入治疗现状, objectType=article, longId=163291, objectId=2b3e16329120, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b3e16329120, replyNumber=0, likeNumber=75, createdTime=2019-04-23, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b3e16329120, moduleTitle=第十七届中国介入心脏病学大会（CIT2019）|蒋世良：中国先心病介入治疗现状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b3e16329120)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738538, encodeId=f69b1e385389e, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=FDA授予Baricitinib快速通道资格用于治疗系统性红斑狼疮, objectType=article, longId=155813, objectId=6c121558133c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c121558133c, replyNumber=0, likeNumber=61, createdTime=2019-08-21, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c121558133c, moduleTitle=FDA授予Baricitinib快速通道资格用于治疗系统性红斑狼疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c121558133c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738546, encodeId=ad4b1e38546f3, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=第十七届中国介入心脏病学大会（CIT2019)|朱鲜阳：结构性心脏病介入治疗并发症及其防治, objectType=article, longId=163320, objectId=e7cf16332087, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7cf16332087, replyNumber=0, likeNumber=93, createdTime=2019-05-07, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7cf16332087, moduleTitle=第十七届中国介入心脏病学大会（CIT2019)|朱鲜阳：结构性心脏病介入治疗并发症及其防治, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7cf16332087)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738543, encodeId=850c1e38543f4, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=第十七届中国介入心脏病学大会（CIT2019)|王海昌：ACS急诊PCI术中并发症紧急处理技巧, objectType=article, longId=163265, objectId=542d16326544, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=542d16326544, replyNumber=0, likeNumber=122, createdTime=2019-08-17, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=542d16326544, moduleTitle=第十七届中国介入心脏病学大会（CIT2019)|王海昌：ACS急诊PCI术中并发症紧急处理技巧, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=542d16326544)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738537, encodeId=50d21e385370b, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=JCC： JAK激酶抑制剂Peficitinib在治疗中重度UC中有良好效果, objectType=article, longId=153224, objectId=b6d91532243b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6d91532243b, replyNumber=0, likeNumber=60, createdTime=2019-08-03, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6d91532243b, moduleTitle=JCC： JAK激酶抑制剂Peficitinib在治疗中重度UC中有良好效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6d91532243b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738531, encodeId=61911e3853194, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=CLIN CANCER RES：Guadecitabine联合卡铂治疗铂类耐药复发卵巢癌, objectType=article, longId=139686, objectId=ff45139686f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff45139686f9, replyNumber=0, likeNumber=53, createdTime=2018-09-13, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff45139686f9, moduleTitle=CLIN CANCER RES：Guadecitabine联合卡铂治疗铂类耐药复发卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff45139686f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CIT

2020-05-29

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

City of Hope正在招募患者进行HPV相关癌症的人体T细胞试验

2020-03-18

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

每周一次的somapacitan治疗生长激素缺乏症儿童，效果与每日一次的生长激素相当

2019-10-23

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

第十七届中国介入心脏病学大会（CIT2019)|寿锡凌：ACS合并高出血风险患者PCI术后双抗的复杂性

2019-04-15

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Lancet：Upadacitinib单药是否可替代甲氨蝶呤治疗类风湿性关节炎？

2020-02-09

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

第十七届中国介入心脏病学大会（CIT2019)|高鑫：经皮肺动脉血管成形术围术期管理

2019-11-11

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Lancet：Upadacitinib单药治疗甲氨蝶呤应答不充分的类风湿性关节炎

2019-07-29

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Resuscitation：3.9万猝死人群研究，三成猝死者在事发前三月内曾去过急诊科

2020-03-02

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

第十七届中国介入心脏病学大会（CIT2019)|徐仲英：老年人房间隔缺损的介入治疗

2019-07-21

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

MedSci期刊数据库中更新全新citescore

2019-11-20

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

The Lancet：Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果

2020-02-03

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

NEJM：sacituzumab govitecan-hziy治疗难治性转移性三阴性乳腺癌

2019-11-01

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

AbbVie向美国FDA提交Upadacitinib治疗中重度类风湿性关节炎的新药申请

2019-09-09

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

第十七届中国介入心脏病学大会（CIT2019)|陈韵岱：心肌微循环灌注的评价方法

2020-03-12

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

第十七届中国介入心脏病学大会（CIT2019)|傅向华：急性心肌梗死再灌注治疗与微循环保护进展

2020-02-26

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

第十七届中国介入心脏病学大会（CIT2019）|蒋世良：中国先心病介入治疗现状

2019-04-23

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

FDA授予Baricitinib快速通道资格用于治疗系统性红斑狼疮

2019-08-21

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

第十七届中国介入心脏病学大会（CIT2019)|朱鲜阳：结构性心脏病介入治疗并发症及其防治

2019-05-07

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

第十七届中国介入心脏病学大会（CIT2019)|王海昌：ACS急诊PCI术中并发症紧急处理技巧

2019-08-17

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

JCC： JAK激酶抑制剂Peficitinib在治疗中重度UC中有良好效果

2019-08-03

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

CLIN CANCER RES：Guadecitabine联合卡铂治疗铂类耐药复发卵巢癌

2018-09-13

科室
- - 订阅+
  - 更多科室
工具
服务